Combined Androgen Deprivation Therapy and Radiation Therapy for Locally Advanced Prostate Cancer:Positive Results

A group of researchers just reported positive results of a phase 3 trial showing that the addition of radiation therapy (RT) improves overall survival in men with locally advanced prostate cancer (T3 & T4) to androgen deprivation therapy (ADT) alone. The researchers used a sample of 1,057 men with locally advanced (T3 or T4) prostate [...]

Identifying A New Pathway Explaining Resistance to Prostate Cancer Treatment

We al are very familiar with the significant problem in the treatment of prostate cancer, even therapies that initially work stop working and our disease continues to progress. The inevitable onset of this resistance to treatment with antiandrogens (ADT) such as Lupron or Zoladex is not limited just to this class of drugs. We have [...]

Towards An Understanding of the Role of Genetics in Determining Future Treatment Options in Advanced Prostate Cancer – SLCO2B1 and SLCO1B3

We have heard for a period of time that the future of cancer treatment is in genetics. Despite the hubbub, we see very little hard evidence of this in today’s current treatment decisions. Treatment still remains tied into protocols with a strong bias to following a common map. Each map does have little variances, but [...]

Intermittent Androgen Deprivation (IAD)- No Longer Considered Experimental for Treating Men with Advanced Prostate Cancer

Changing the Standard of Care for Men with Recurrent and Advanced Prostate Cancer, Men receiving androgen deprivation therapy (ADT) for the treatment of advanced or metastatic prostate cancer know all to well the terrible side effects this treatment modality can cause. These side effects can include fatigue, hot flashes, mood swings, inability to concentrate as [...]

An Official Release of the Exciting Results of the Abiraterone Acetate (Zytiga) Trial

Today’s big news is about a media release made yesterday by Centocor Ortho Biotech with the official and final results of the Phase III clinical trial of abiraterone acetate (Zytiga™) plus prednisone vs. prednisone alone in men with metastatic, castration-resistant prostate cancer (mCRPC) who have already received at least one course of a docetaxel based [...]

Go to Top